Paradigm Biopharmaceuticals Ltd. reported top-line data from its phase II trial of Zilosul (pentosan polysulfate/PPS) that suggest the non-opioid treatment for knee osteoarthritis is effective in navigating pain management but also has the potential to be disease modifying.
Researchers from Guangzhou Medical University (GMU) described the discovery of a novel proteasome inhibitor NIC-0102, being developed as an anti-inflammatory therapeutic candidate.
Pathogen-associated molecular patterns (PAMPs) are by themselves not enough to set off a full innate immune response to viral infection. Instead, structural changes to the actin cytoskeleton primed the activation of RIG-I-like receptors (RLRs), a family of intracellular RNA sensors that detect many types of viral RNA. When primed RLRs then encountered viral RNA, they set off an innate immune response that led to the production of interferons.
Gentibio Inc. has announced preclinical data relating to the company's platform technology, demonstrating technical progress to engineer regulatory T cells (Tregs) for the prevention and treatment of autoimmune diseases.
Following a research program to identify inhibitors of protein kinases TBK1 and IKK-ε, Domainex Ltd. has nominated DMXD-011 as a preclinical drug candidate.
“The association between air pollution and lung cancer is not new,” Charles Swanton told the audience at the European Society of Medical Oncology (ESMO) 2022 Congress. But as with so many associations, causation has been hard to establish, partly due to the puzzling absence of mutations.
Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.
Arcutis Biotherapeutics Inc. has entered into an agreement to acquire Ducentis Biotherapeutics Inc., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.
RSS
